公开(公告)号：US20240238380A1

公开(公告)日：2024-07-18

申请号：US18562322

申请日：2022-05-20

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Do Hoon KIM ,  Mi Kyeong JU ,  Hyun Ho CHOI ,  Han Na HONG ,  Junhwan KIM

IPC: A61K38/26 ,  A61K38/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

CPC classification number: A61K38/26 ,  A61K38/1841 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome by administering in combination with a GLP-1 (glucagon-like peptide-1) receptor agonist, comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

公开(公告)号：US20240082354A1

公开(公告)日：2024-03-14

申请号：US18513613

申请日：2023-11-19

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Do Hoon KIM ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Nayeon YANG ,  Junhwan KIM

IPC: A61K38/18 ,  A61P1/16

CPC classification number: A61K38/1841 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

公开(公告)号：US20230002460A1

公开(公告)日：2023-01-05

申请号：US17779932

申请日：2020-11-25

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Young Bong PARK ,  Sukyung KIM ,  Bo Ra SIM ,  Wonee CHONG ,  Hyun Ho CHOI ,  Ji Eun YANG ,  Mi Kyeong JU ,  Won Tae KIM ,  Youn Woo LEE ,  Junhwan KIM

IPC: C07K14/475 ,  C12N15/63

Abstract: A fusion protein including a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition containing the same are disclosed. The GDF15 variant or long-acting GDF15 fusion protein is superior to conventional GDF15 variants in terms of in vitro efficacy, binding affinity for GDF15 receptors, and body weight loss effect. Therefore, a pharmaceutical composition containing, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or a dimer of the fusion protein, causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity. Furthermore, the pharmaceutical composition can be used in combination therapy or the like with chemical drugs and other therapeutic agents for metabolic diseases, and can be effectively used in combination therapy with conventional therapeutic agents for metabolic diseases or obesity.